FDA Drug Recalls

Recalls / Class II

Class IID-0230-2026

Product

3% Polocaine DENTAL, Mepivacaine Hydrochloride 3% (30mg/mL) (Mepivacaine HCI Injection, USP), packaged in a carton containing 50 single-dose Cartridges, 1.7 ml each, Rx only, Manufactured for Dentsply Pharmaceutical, York, PA 17404, by Novocol Pharmaceutical of Canada, Inc., NDC 66312-441-16.

Brand name
Polocaine
Generic name
Mepivacaine Hydrochloride
Active ingredient
Mepivacaine Hydrochloride
Route
Submucosal
NDC
66312-441
FDA application
ANDA088387
Affected lot / code info
Lot: D05159C, expires: 07-31-2027

Why it was recalled

Defective container: cracked/broken cartridges

Recalling firm

Firm
Novocol Pharmaceutical of Canada, Inc.
Manufacturer
Dentsply Pharmaceutical
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
25 Wolseley Crt, Cambridge, N/A, Canada

Distribution

Quantity
5,825
Distribution pattern
U.S.A. Nationwide

Timeline

Recall initiated
2025-10-31
FDA classified
2025-12-12
Posted by FDA
2025-12-24
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0230-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Polocaine · FDA Drug Recalls